ClinicalTrials.gg
RecruitingNCT06987474Updated Oct 30, 2026

Capella Scientia Development Study

An observational study in Cataract, sponsored by Alcon Research. Recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Alcon Research (part of Alcon) · Observational

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 30, 2026First site in United States1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 116 studies in Cataract by Alcon — 4 open to participants now, 6 under way, none of them phase 3. Cataract · Alcon.

Planned enrollment
3rd of 12
400 · median 145
Started
2025
with 4 others
Observational
12 of 116
2 open now
Registered
109th of 116
by date

Among the 116 studies in Cataract by Alcon, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2025, is one of 12 observational ones, and was the 109th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

4 of the 116 studies in Cataract by Alcon are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Cataract by Alcon, or all of them as a file.
02

Study summary

This study involves collecting biometry and aberration data using the next generation biometer, Unity DX.

Read the detailed description

In this prospective, noninterventional, single-arm, unmasked, multicenter study, 4 different subject cohorts will be enrolled simultaneously to collect biometry and aberrometry data using Unity DX. This study will be conducted in the US, India, Spain, and the Philippines.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects will be recruited from clinical sites located in India, Spain, and the Philippines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and sign an IRB/IEC approved consent form;
  • Willing and able to attend study visit(s) as required by the protocol;
  • Consenting age at the jurisdiction of study site;
  • Other group-specific, protocol required inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Women of ;
  • Unable to fixate due to nystagmus or other eye movement abnormality (e.g., significant strabismus);
  • Unclear optical media preventing data capture from all devices in the study;
  • for pupil dilation (e.g., narrow angles, allergies) per investigator's clinical judgment;
  • Any ocular disease and/or condition that, in the investigator's clinical judgment, may put the subject at significant risk, may compromise study results, or may interfere significantly with the subject's participation in the study;
  • Other group-specific, protocol required exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Subjects/eyes previously implanted with an Alcon monofocal or multifocal presbyopia correcting IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.

    Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer

  • Group 2

    Subjects/eyes with planned implantation of an Alcon monofocal or monofocal toric IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.

    Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer

  • Group 3

    Subjects/eyes with with prior refractive surgery such as LASIK or PRK and planned implantation of an Alcon monofocal or monofocal toric IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.

    Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer

  • Group 4

    Subjects/eyes with keratoconus, a progressive cornea disorder. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.

    Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer

Interventions

  • DeviceUnity DX and SMARTCataract DX (SCDX) Biometer

    Unity DX is a CE-marked, noninvasive, noncontact instrument that generates a 3D model of the eye using hyper parallel optical coherence tomography (HP OCT), aberrometry, and topography. The current version of SCDX software will be used in this study.

  • DeviceIOLMaster 700 Biometer

    The IOLMaster 700 Biometer is a CE-marked, noninvasive, noncontact instrument that captures optical biometry. Data will be collected using standard clinical assessments.

  • DeviceArgos with Alcon Image Guidance Biometer

    The Argos with Alcon Image Guidance biometer is a CE-marked, noninvasive, noncontact instrument that will capture optical biometry. Data will be collected using standard clinical assessments.

06

What researchers measure

Primary outcomes

  1. Manifest Refraction Spherical Equivalent (MRSE)

    A manifest refraction (manual refraction) will be performed using a phoropter. The spherical equivalent is calculated by adding the sum of the sphere power with half of the cylinder power. MRSE will be reported in diopters.

    Time frame: Group 1 and Group 4: Day 0; Group 2 and Group 3: Screening (Day -30 to Day -1), Day 30 to 60 postoperative, Day 70 to 100 postoperative

07

Study locations

4 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 67 industry-sponsored observational studies under Cataract, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 22 months is above that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 23, 2025
StartActual
Jul 30, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • The Eye Institute of Utah · Salt Lake City, United States
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added — first site in United States
    Show site
    • The Eye Institute of Utah · Salt Lake City, United States
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06987474
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Jul 30, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Alcon Call Center
Contact
alcon.medinfo@alcon.com
1-888-451-3937
Principal II, Clinical Trial Operations, Vision Care
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion